Welcome to our dedicated page for Innate Pharma S.A. ADS news (Ticker: IPHA), a resource for investors and traders seeking the latest updates and insights on Innate Pharma S.A. ADS stock.
Innate Pharma S.A. (Symbol: IPHA) is a clinical-stage biotechnology company at the forefront of cancer treatment innovation. Specializing in immuno-oncology, Innate Pharma develops first-in-class therapeutic antibodies designed to harness the innate immune system. This pioneering approach helps the body's natural defenses recognize and combat cancer cells more effectively.
The company's diverse pipeline includes four clinical-stage antibodies along with several preclinical candidates. Key products under development include lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401, and IPH6501. These therapies aim to address a wide range of cancer types, particularly those with high unmet medical needs.
Innate Pharma has made significant strides in the discovery and development of checkpoint inhibitors, leveraging its deep understanding of natural killer cell biology. This expertise has led to strategic partnerships with renowned biopharmaceutical companies such as AstraZeneca, Bristol-Myers Squibb, Novo Nordisk A/S, and Sanofi.
The company’s revenue streams primarily come from research collaborations, licensing agreements, and milestone payments from its pharmaceutical partners. Innate Pharma's proprietary platform, ANKET (Antibody-based NK cell Engager Therapeutics), forms the backbone of its innovative therapeutic strategies.
With a commitment to advancing cancer treatment, Innate Pharma continues to make significant progress in clinical trials and research, aiming to bring transformative therapies to patients worldwide.
Innate Pharma has announced the filing of a prospectus supplement with the SEC for a new At-The-Market (“ATM”) program, allowing for the offering of up to
Innate Pharma (Euronext Paris: IPH; Nasdaq: IPHA) announced its participation in the Van Lanschot Kempen Life Sciences Conference 2023 on April 25-26 in
Innate Pharma SA (Euronext: IPH; Nasdaq: IPHA) reported its total number of shares outstanding and voting rights as of April 1, 2023. The company has a total of 80,222,007 ordinary shares and 6,514 and 7,581 preferred shares from 2016 and 2017, respectively. The total number of theoretical voting rights stands at 80,979,847, with 80,961,272 exercisable voting rights. These figures comply with the French 'Code de Commerce' and AMF regulations. As a clinical-stage biotechnology firm, Innate focuses on developing immunotherapies for cancer using its proprietary ANKET® platform, partnering with major firms like Sanofi and AstraZeneca to enhance its R&D efforts.
FAQ
What is the current stock price of Innate Pharma S.A. ADS (IPHA)?
What is the market cap of Innate Pharma S.A. ADS (IPHA)?
What does Innate Pharma S.A. specialize in?
What are some of Innate Pharma's key products?
How does Innate Pharma generate revenue?
Who are some of Innate Pharma's notable partners?
What is ANKET?
What is the focus of Innate Pharma’s current projects?
What stage is Innate Pharma in?
What makes Innate Pharma's approach unique?
What is immuno-oncology?
How does Innate Pharma contribute to cancer research?
